- Home
- TLSI vs DERM Comparison
TLSI vs DERM Comparison
Compare TLSI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- DERM
- Stock Information
- Founded
- TLSI 2010
- DERM 2014
- Country
- TLSI United States
- DERM United States
- Employees
- TLSI N/A
- DERM N/A
- Industry
- TLSI Medical Specialities
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- DERM Health Care
- Exchange
- TLSI Nasdaq
- DERM Nasdaq
- Market Cap
- TLSI 124.9M
- DERM 116.8M
- IPO Year
- TLSI N/A
- DERM 2021
- Fundamental
- Price
- TLSI $3.95
- DERM $4.92
- Analyst Decision
- TLSI Strong Buy
- DERM Strong Buy
- Analyst Count
- TLSI 6
- DERM 3
- Target Price
- TLSI $11.75
- DERM $9.50
- AVG Volume (30 Days)
- TLSI 52.7K
- DERM 110.0K
- Earning Date
- TLSI 11-14-2024
- DERM 11-12-2024
- Dividend Yield
- TLSI N/A
- DERM N/A
- EPS Growth
- TLSI N/A
- DERM N/A
- EPS
- TLSI N/A
- DERM N/A
- Revenue
- TLSI $26,891,000.00
- DERM $57,771,000.00
- Revenue This Year
- TLSI $60.97
- DERM N/A
- Revenue Next Year
- TLSI $53.69
- DERM $36.49
- P/E Ratio
- TLSI N/A
- DERM N/A
- Revenue Growth
- TLSI 67.90
- DERM N/A
- 52 Week Low
- TLSI $3.50
- DERM $2.85
- 52 Week High
- TLSI $10.42
- DERM $8.11
- Technical
- Relative Strength Index (RSI)
- TLSI 46.18
- DERM 37.05
- Support Level
- TLSI $3.76
- DERM $4.75
- Resistance Level
- TLSI $4.17
- DERM $5.19
- Average True Range (ATR)
- TLSI 0.35
- DERM 0.28
- MACD
- TLSI -0.04
- DERM -0.07
- Stochastic Oscillator
- TLSI 33.66
- DERM 5.36
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.